Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET
Company Participants
Allison Wey – Senior Vice President of Investor Relations & Corporate Communications
John P. Shannon – CEO & Director
Steven M. Pieper – Chief Financial Officer
Conference Call Participants
Alexandra Doering von Riesemann – Piper Sandler & Co., Research Division
Chase Richard Knickerbocker – Craig-Hallum Capital Group LLC, Research Division
Christian J. Clark – Leerink Partners LLC, Research Division
Jason Dorr – Oppenheimer & Co. Inc., Research Division
Operator
Hello, everyone, and thank you for joining the Xeris Biopharma Second Quarter 2025 Earnings Conference Call. My name is Sami, and I’ll be coordinating your call today. [Operator Instructions] I’ll now hand over to your host, Allison Wey, Senior Vice President of Investor Relations and Corporate Communications, to begin. Please go ahead, Allison.
Allison Wey
Thank you, Sami. Good morning, everyone, and thank you for joining our call today. I’m joined with John Shannon, our CEO; and Steve Pieper, our CFO. Earlier this morning, we issued a press release with our detailed results, which can be found on our website. After our prepared remarks, we will open the line for questions.
Before we begin, I’d like to remind you that this call will contain forward-looking statements concerning the company’s future expectations, plans, projects and financial performance. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those forward-looking statements. For more information on our risks, please refer to our earnings release and the risk factors included in our SEC filings.
Any forward-looking statements in this call represent our views only as of the date of this call and subject to applicable laws, we disclaim any obligation to update such statements. Please note, some metrics we will discuss today are
#Xeris #Biopharma #Holdings #XERS #Earnings #Call #Transcript